| Population 2016 |
29 million |
| |
| | | | | |
| Estimates of TB burden*, 2016 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
18 |
(10–29) |
64 |
(36–99) |
| Mortality (HIV+TB only) |
6.9 |
(3.4–12) |
24 |
(12–41) |
| Incidence (includes HIV+TB) |
107 |
(66–156) |
370 |
(230–543) |
| Incidence (HIV+TB only) |
18 |
(8.5–30) |
61 |
(29–104) |
| Incidence (MDR/RR-TB)** |
4.3 |
(1.4–7.3) |
15 |
(4.8–25) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2016 |
| |
0-14 years |
> 14 years |
Total |
| Females |
5.1 |
(2.9–7.2) |
35 |
(20–50) |
40 |
(23–58) |
| Males |
5.8 |
(3.3–8.3) |
60 |
(35–86) |
66 |
(38–94) |
| Total |
11 |
(6.3–16) |
96 |
(55–136) |
107 |
(66–156) |
| |
| | | | | |
| TB case notifications, 2016 |
|
| Total cases notified |
60 916 |
| Total new and relapse |
59 513 |
| - % tested with rapid diagnostics at time of diagnosis |
<1% |
| - % with known HIV status |
46% |
| - % pulmonary |
93% |
| - % bacteriologically confirmed among pulmonary |
54% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2016 |
56% (38–90) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 |
0.25 (0.13–0.4) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2016 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
2 765 |
10% |
| - on antiretroviral therapy |
|
|
| |
| | | | | |
| Drug-resistant TB care, 2016 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
2 600
(790–4 400) |
| Estimated % of TB cases with MDR/RR-TB |
2.6% (0.1–5.1) |
18% (0.1–36) |
|
| % notified tested for rifampicin resistance |
<1% |
4% |
452 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 167, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 334, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2015 |
|
|
| Previously treated cases, excluding relapse, registered in 2015 |
|
|
| HIV-positive TB cases registered in 2015 |
|
|
| MDR/RR-TB cases started on second-line treatment in 2014 |
43% |
249 |
| XDR-TB cases started on second-line treatment in 2014 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2016 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2017 |
|
| National TB budget (US$ millions) |
14 |
| Funding source: 29% domestic, 19% international, 52% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed | | |
| | | | | |